Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-16T17:24:12.918Z Has data issue: false hasContentIssue false

Response from Neurolink

Published online by Cambridge University Press:  02 January 2018

G. Jackson
Affiliation:
Neurolink, Middlesex House, 34 Cleveland Street, London WIP 5FB, UK
T. Brown
Affiliation:
St John's Hospital, Livingston, UK
J. Butler
Affiliation:
Bedfordshire and Luton Community NHS Trust, Bedfordshire, UK
P. Cowen
Affiliation:
Warneford Hospital, Oxford, UK
C. Freeman
Affiliation:
Royal Edinburgh Hospital, Edinburgh, UK
H. Freeman
Affiliation:
Green College, Oxford, UK
L. Gask
Affiliation:
University of Manchester, Manchester, UK
G. Kassianos
Affiliation:
Bracknell PCG, Birch Hill Medical Centre, Bracknell, UK
A. Kirby
Affiliation:
Health Media Ltd, Cardiff, UK
S. Koppel
Affiliation:
Glan Rhyd Hospital, Bridgend, UK
D. Nutt
Affiliation:
University of Bristol, Bristol, UK
P. Shaw
Affiliation:
Maidenhead PCG, William Symons Medical Centre, Maidenhead, UK
C. Vardy
Affiliation:
Gateshead PCG, Gateshead, UK
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © 2002 The Royal College of Psychiatrists 

The members of Neurolink were particularly disturbed by Dr Wright's accusation that the materials produced by Neurolink are unbalanced and favour venlafaxine, manufactured by Wyeth.

Neurolink is a well-established board of 14 mental health experts who pride themselves on their unbiased, professional expertise in anxiety and depression, and their ability, as a multi-disciplinary group of health care professionals, to produce materials of practical value to other health care professionals and patients.

Neurolink is indeed supported by an educational grant from Wyeth Laboratories, and has been since 1995. Board members receive an honorarium for their attendance at Advisory Board meetings and working parties, where production of materials is discussed and agreed in the light of the existing evidence base and consensus of the members of the Board.

We would like to emphasise that the materials produced by Neurolink are balanced items that review all treatment options — including drug and non-drug options — and we would refute all claims that materials give prominence to venlafaxine, or any other drug or treatment, unless there is a body of significant evidence that supports it. In the 6 years that we have been in existence, we have never previously received comments to suggest that Neurolink materials are not impartial, practical resource items.

References

EDITED BY MATTHEW HOTOPF

Submit a response

eLetters

No eLetters have been published for this article.